Skip to main content
. 2017 Aug 1;8(35):59476–59491. doi: 10.18632/oncotarget.19761

Figure 7. Genetic inhibition of CDK9 or cyclin T1 potentiates BH3-mimetic lethality in MM cells.

Figure 7

(A and C) U266 cells were stably transfected with constructs encoding shRNA targeting cyclin T1 (A) or shRNA targeting CDK9 (C) or scrambled sequence (shNC). Cells were then treated with 500-750 nM ABT-737 for 24 hr, and cell death was analyzed by flow cytometry after staining with 7-AAD. * = P < 0.05, significantly greater than control. (B and D) Following treatment as described above, immunoblotting analysis was carried out to monitor serine-2 phosphorylation of the CTD of RNA pol II, cyclin T1, CDK9, cleaved caspase 3, and Mcl-1. Each lane was loaded with 30 μg of protein; α-tubulin controls were assayed to ensure equivalent loading and transfer.